Accepted Manuscript

CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han



Jie-Ya Wang, Yan-Jiao Zhang, He Li, Xiao-Lei Hu, Mu-Peng Li, Pei-Yuan Song, Qi-Lin Ma, Li-Ming Peng, Xiao-Ping Chen

PII:	80378-1119(18)30889-8
DOI:	doi:10.1016/j.gene.2018.08.027
Reference:	GENE 43146
To appear in:	Gene
Received date:	8 May 2018
Revised date:	29 July 2018
Accepted date:	6 August 2018

Please cite this article as: Jie-Ya Wang, Yan-Jiao Zhang, He Li, Xiao-Lei Hu, Mu-Peng Li, Pei-Yuan Song, Qi-Lin Ma, Li-Ming Peng, Xiao-Ping Chen, CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han. Gene (2018), doi:10.1016/j.gene.2018.08.027

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

CRISPLD1 rs12115090 Polymorphisms Alters Antiplatelet Potency of Clopidogrel in coronary artery disease patients in Chinese Han

Jie-Ya Wang,^{1,2} Yan-Jiao Zhang,^{1,2} He Li,^{1,2} Xiao-Lei Hu,^{1,2} Mu-Peng Li,^{1,2} Pei-Yuan Song,^{1,2} Qi-Lin Ma³, Li-Ming Peng³, Xiao-Ping Chen^{1,2,4,*}

¹Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, P. R. China
²Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, Hunan, P. R. China
³Department of cardiology, xiangya hospital, Central South University, Changsha 410008, Hunan, P. R. China
⁴National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, P. R. China

*Correspondence to: Professor Xiao-Ping Chen, Tel: +86 731 84805380, Fax: +86 731 82354476, Email: chenxp74@hotmail.com

Abstract

Background: Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is a recommended treatment for coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI) to reduce the rate of ischemic events and stent thrombosis. However, high on-treatment platelet reactivity (HTPR) during clopidogrel therapy for some patients may lead to outcome failure and occurrence of cardiovascular events. Amounts of studies have proved that genetic factors may contribute to HTPR. In our study, we explored the predictive value of 10 single

Download English Version:

https://daneshyari.com/en/article/11033773

Download Persian Version:

https://daneshyari.com/article/11033773

Daneshyari.com